Form 4 for JNJ Johnson & Johnson
Accepted 2025-09-05 18:00:47 ET · period of report 2025-09-04 · accession 0000200406-25-000186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-05 18:00 | 2025-09-04 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $101.87 | +56.5K | 234.5K | +32% | +$5.75M |
| D | 2025-09-05 18:00 | 2025-09-04 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $177.81 | -56.5K | 178.0K | -24% | -$10.04M |
| D | 2025-09-05 18:00 | 2025-09-04 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $101.87 | -56.5K | 0 | -100% | -$5.75M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-04 | M | A | 56,471 | $101.87 | 234,484.00 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-04 | S | D | 56,471 | $177.81 | 178,013.00 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $177.715 to $177.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Employee Stock Options (Right to Buy) | 2025-09-04 | M | D | 56,471 | $101.87 | 0 | D | $101.87 · 2019-02-09 to 2026-02-08 | 56,471 Common Stock | (F2) Vested and exercisable one day after the third anniversary of the date of the grant. |